Wegovy and Back Pain: Does Semaglutide Cause It or Help It?

Is back pain listed as a side effect of Wegovy?

Yes. Back pain appears in the product's clinical trial safety data and is included in the prescribing information for semaglutide 2.4 mg. It sits in the category of reported musculoskeletal effects, distinct from the gastrointestinal side effects (nausea, loose stools, indigestion) that tend to get the most attention when people read about Wegovy.

In the STEP 1 trial (68 weeks, published in the New England Journal of Medicine), the headline finding was around 15% average weight reduction at 2.4 mg semaglutide, but the full safety tables recorded musculoskeletal complaints including back pain at a rate that was meaningful enough to include in the summary. It was not the most frequent event (that distinction belongs firmly to GI effects) but it was not rare either.

The honest answer is that clinical trial populations are carefully selected and monitored, so real-world rates may differ. People often come to Wegovy carrying existing back problems that weight and metabolic conditions made worse over years. Disentangling what the medicine causes versus what the underlying condition was doing anyway is genuinely difficult. That is why the prescriber relationship matters: someone who knows your starting point can interpret new symptoms in context. For a deeper look at the specific question of causation, this page explores whether Wegovy directly causes back pain.

Could weight loss itself be changing how your back feels?

This is an angle that does not get enough attention. When body weight drops by several kilograms over the first months of treatment, the mechanical load on the lumbar spine, the hip flexors and the paraspinal muscles changes. For many people that change is welcome and gradual. But the spine is not a passive structure: it adapts, and adaptation sometimes involves temporary discomfort.

Muscles that have spent years supporting a particular load pattern may feel different as that load shifts. Ligaments and intervertebral discs that were compressed in one way are now being used differently. In some people this produces a period of mild aching or stiffness, particularly in the lower back. Lower back pain specifically during Wegovy treatment is something a number of patients report in the early and middle phases, and it often settles as the body adjusts.

Separately, reduced appetite can lead some people to move less and eat less protein than their muscles need, which over time can contribute to muscle weakness around the spine. Keeping protein intake adequate and maintaining some form of strengthening activity matters during GLP-1 treatment — your prescriber or a dietitian can help you set realistic targets. The NHS England guidance on weight management injections highlights the importance of lifestyle support running alongside treatment.

When is back pain a warning sign that needs urgent attention?

Most back pain during Wegovy is musculoskeletal: dull, positional, related to movement. There is a different and more serious symptom pattern that must not be confused with it. Severe stomach or abdominal pain that spreads through to the back, especially when it is persistent and accompanied by vomiting, is a recognised warning sign for acute pancreatitis.

In January 2026 the MHRA issued a Drug Safety Update for GLP-1 medicines confirming acute pancreatitis as a known but infrequent serious effect, and advising patients and clinicians to treat this specific pain pattern as a reason to seek urgent medical help. The symptom tends to sit deep in the abdomen rather than in the back muscles themselves, but the radiation pattern means people sometimes describe it as back pain. If you experience this, stop treatment and get medical help promptly, do not wait for your next scheduled appointment.

Other reasons to contact a prescriber or GP without delay include back pain alongside urinary symptoms (possible kidney involvement, particularly if severe GI illness has led to dehydration) or any new neurological symptoms in the legs. For broader questions about GI-related discomfort on semaglutide, this page covers gas and abdominal pain during Wegovy treatment. If you are unsure whether what you are feeling is ordinary muscular soreness or something that needs assessment, err on the side of contacting your clinical team.

What should you do if back pain continues throughout your course?

Mild, variable back pain that comes and goes and does not fit the pancreatitis picture is worth monitoring but not necessarily a reason to stop treatment. Keep a rough note of when it appears, how long it lasts and whether anything relieves it. That log is genuinely useful for a prescriber: patterns tell a story that a single reported symptom does not.

If the pain is persistent, worsening, or affecting your sleep and daily function, it warrants a clinical conversation before your next scheduled review. A prescriber may consider whether the dose increase that preceded it is relevant, whether the rate of weight change is a factor, or whether an independent musculoskeletal problem needs separate assessment. Treatments are reviewed before every repeat at nume, there is no automatic continuation. Our clinical team fields questions like this regularly. People sometimes time their queries around a Monday order or before a bank holiday stretch when they know getting hold of a GP will be harder, our aftercare runs seven days a week precisely for those moments.

If you are considering starting Wegovy and want to discuss your history of back problems as part of the eligibility assessment, you can find full details of the treatment options we offer at our weight-loss treatments page. You can also read more about how Wegovy works, what treatment costs in the UK, and what happens to your weight if you stop taking Wegovy before you start your free consultation.